Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Sustainability Profile
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a leading biopharmaceutical company based in China, focuses on innovative drug discovery and development. Founded in 2015, the company has rapidly established itself in the biotechnology sector, with its headquarters in Beijing and operational reach across major regions in China. Specialising in monoclonal antibodies and gene editing technologies, Biocytogen is renowned for its unique animal models that facilitate advanced preclinical research. The company’s commitment to innovation has positioned it as a key player in the global biopharmaceutical landscape, with notable achievements in therapeutic development and collaborations with various research institutions. With a strong emphasis on quality and scientific excellence, Biocytogen continues to drive advancements in the industry, contributing significantly to the future of healthcare solutions.
DitchCarbon Score
How does Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s reported carbon emissions
In 2022, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. reported greenhouse gas emissions data, although specific total emissions figures in kg CO2e were not disclosed. The company provided emission intensity metrics, indicating a greenhouse gas emission intensity of approximately 200 kg CO2e per square metre and 0.00043 kg CO2e per RMB 1,000 expenditure. However, there is no available data on Scope 1, 2, or 3 emissions. Biocytogen has not set any specific reduction targets or climate pledges, nor are there any initiatives reported under the Science Based Targets initiative (SBTi). The absence of disclosed reduction initiatives suggests that the company may still be in the early stages of formalising its climate commitments. As of now, Biocytogen Pharmaceuticals does not inherit emissions data from a parent or related organisation, indicating that its climate strategy is independently developed. The company operates within a growing industry context where many pharmaceutical firms are increasingly focusing on sustainability and carbon reduction strategies.
How Carbon Intensive is Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s Industry?
How Carbon Intensive is Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s Location?
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
